News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Less Than Two Weeks Remain before Deadline in Class-Action Lawsuit Against Dendreon Corporation, Says Hagens Berman
September 22, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SEATTLE--(BUSINESS WIRE)--Hagens Berman Sobol Shapiro LLP reminds investors that those who wish to serve as lead plaintiff in a class-action lawsuit against Dendreon (NASDAQ:DNDN) have less than two weeks from today to file their motion.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Government
After Speaking out of Turn, Malone Steps Down From Vaccine Committee
March 27, 2026
·
2 min read
·
Tristan Manalac
Government
HHS Denies Disbandment of CDC Vaccine Advisory Group in Wake of Court Ruling
March 20, 2026
·
2 min read
·
Tristan Manalac
Policy
FDA Policy Tracker 2026: RMAT Awards for Assets on Hold, Animal Testing Alternatives
March 19, 2026
·
9 min read
·
BioSpace Editorial Staff
Legal
Kennedy’s Vaccine Policy Overhaul Stymied by Federal Judge
March 17, 2026
·
3 min read
·
Tristan Manalac